
DENTSPLY SIRONA (XRAY) Stock Forecast & Price Target
DENTSPLY SIRONA (XRAY) Analyst Ratings
Bulls say
Dentsply Sirona's sales in Europe experienced a reported growth of 2.8% and an organic growth of 1.8%, indicating a steady demand for its dental products in a significant market. Furthermore, the company's subsidiary, Wellspect Healthcare, generated $81 million in revenue, surpassing consensus estimates and achieving an organic growth rate of 6.7% in the fourth quarter of 2024, highlighting strong performance and product innovation. Overall, there are anticipations of accelerating revenue growth into the mid-single digits in the coming years, driven by factors such as market share gains in clear aligners, recovery in the implants sector, and ongoing margin improvements.
Bears say
Dentsply Sirona's financial outlook is negatively impacted by a significant shortfall in profitability, with an adjusted EPS of $0.26, falling well below expectations of $0.43. The company's connected technology solutions segment experienced an 8.3% decline in revenue, indicating ongoing challenges, while the Byte shutdown alone accounted for a $62 million loss in revenue and a $0.24 reduction in adjusted EPS. Additionally, increasing operating expenses and a gross margin contraction of 240 basis points year-over-year further exacerbate concerns about the company's financial stability and future growth prospects.
This aggregate rating is based on analysts' research of DENTSPLY SIRONA and is not a guaranteed prediction by Public.com or investment advice.
DENTSPLY SIRONA (XRAY) Analyst Forecast & Price Prediction
Start investing in DENTSPLY SIRONA (XRAY)
Order type
Buy in
Order amount
Est. shares
0 shares